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Testing for autoantibodies (AABs) is becoming more and more relevant, not only for diag-
nosing autoimmune diseases (AIDs) but also for the differentiation of defined AID subtypes
with different clinical manifestations, course and prognosis as well as the very early diagnosis
for adequate management in the context of personalized medicine. A major challenge to
improve diagnostic accuracy is to harmonize or even standardize AAB analyses. This
review presents the results of the 12th Dresden Symposium on Autoantibodies that focused
on several aspects of improving autoimmune diagnostics. Topics that are addressed include
the International Consensus on ANA Patterns (ICAP) and the International Autoantibody
Standardization (IAS) initiatives, the optimization of diagnostic algorithms, the description
and evaluation of novel disease-specific AABs as well as the development and introduc-
tion of novel assays into routine diagnostics. This review also highlights important devel-
opments of recent years, most notably the improvement in diagnosing and predicting
the course of rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies,
and of autoimmune neurological, gastrointestinal and liver diseases; the potential
diagnostic role of anti-DFS70 antibodies and tumor-associated AABs. Furthermore,
some hot topics in autoimmunity regarding disease pathogenesis and management are
described. Lupus (2016) 25, 787–796.
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Introduction
At the 12th Dresden Symposium on
Autoantibodies, held in Germany in September
2015, 145 papers were presented that focused on
novel aspects of autoantibody (AAB) research
and diagnostics. This symposium, entitled
‘‘From Autoantibody Research to Standardized
Diagnostic Assays in the Management of Human
Diseases,’’ was organized by the Institute of
Immunology of the Medical Faculty of the
Technical University Dresden in cooperation
with the Association for the Advancement of
Immune Diagnostics (www.gﬁd-ev.de) and the
Immunodiagnostics Section of the German
Society for Clinical Chemistry and Laboratory
Medicine (www.dgkl.de). As the central theme of
the Congress was standardization and harmoniza-
tion of AAB testing, special eﬀorts were dedicated
to host the 2nd International Consensus on
ANA Patterns (ICAP) Workshop and the 2nd
International Autoantibody Standardization (IAS)
Workshop on September 22, 2015 as a continu-
ation of the cognate standardization workshops
held at the 12th International Workshop on
Autoantibodies and Autoimmunity (IWAA) in
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Sa˜o Paulo, 2014.1–3 Those who are interested to
read full length articles and abstracts are referred
to the congress book published in parallel to this
meeting,4 and to other articles published in this
issue of Lupus.
Hot topics in autoimmunity
The symposium started with an overview delivered
by Yehuda Shoenfeld (Israel) summarizing known
and novel aspects of the mosaic of autoimmunity.
It is well known that the pathogenesis of auto-
immune diseases (AID) is, with the exception of
the very rare ‘‘monogenic’’ AID, characterized by
a complex interaction of various endogenous (gene
products involved in the response and regulation
of the innate and adaptive immune system, e.g.
Toll-like receptor and HLA-DRB polymorphisms,
hormones) and exogenous (infectious and non-
infectious agents) factors. A genetic defect of
ribonucleotide excision repair as a cause of sclero-
derma-like skin ﬁbrosis was suggested by Axel
Roers (Germany). The research for and the know-
ledge of autoimmunity triggering factors like bis-
phenol A, sodium chloride, smoking, and obesity
(adipokines) may open possibilities of preventing
AID development.5,6 Aaron Lerner (Germany) dis-
cussed the potential role of industrial food additives
(sodium chloride, organic solvents, emulsiﬁers,
gluten, microbial transglutaminase, nanoparticles)
in the autoimmune pathogenesis that may abrogate
human epithelial barrier function.7 Because micro-
bial pathogens as well as the gut microbiome are
important factors associated with AIDs depending
on the genetic background of the individual
patient, Dimitrios P. Bogdanos (Greece) suggested
the autoinfectome approach to study and recognize
the totality of AID-causing infectious agents for a
given disease, including the mechanisms that can
cause the disease.8 The autoinfectome can be
studied in high risk individuals (such as family
members of probands, professionals exposed to
autoimmunity-linked environmental agents) over
time. Multiplex technologies become less costly
and may assist dissecting the complex nature
of the autoinfectome. It is expected that most of
these infectious agents may be preventable and/or
treatable, and could, therefore, represent a set of
risk factors which could be modiﬁed in their own
right. This approach is promising because the clo-
sest possibility of curing AID is immunoablation
followed by autologous stem cell transplantation
(ASST), as discussed by Falk Hiepe (Germany).
The immunoablation/ASST provides the basis for
the regeneration of a novel adaptive immune
system, which is free of autoimmunity and re-estab-
lishes self-tolerance. Because autoreactive immuno-
logical memory is critical for the maintenance of
autoimmunity and refractory to conventional
immunosuppression, the eﬀective depletion of the
autoreactive memory may provide the basis for
treatments with a curative potential. New thera-
peutic strategies should consider the autoreactive
memory as target.
From research to clinical application
The clinical relevance of AABs can be improved by
diﬀerentiating the ﬁne speciﬁcities and the search
for pathogenic epitope speciﬁcities. As has been
shown by Pier Luigi Meroni (Italy), the character-
ization of the epitope speciﬁcity of anti-b2GPI anti-
bodies may oﬀer new tools for improving the
diagnostic/prognostic power of the assay in anti-
phospholipid syndrome.9 He concluded that
immunoassays using domain I peptide for anti-
ß2GPI determination should be further evaluated
and perhaps enter routine diagnostics.10,11 Besides
the importance of epitope speciﬁcity exempliﬁed by
the anti-b2GPI-IgG AAB, the pathogenicity of
AABs also depends on Fc glycosylation.12 Martin
Herrmann (Germany) reviewed the role of Fc
modiﬁcations on the functional diversity of
immunoglobulins that may have implication for
diagnostic procedures (e.g., diﬀerent glycosylation
of AAB in AID patients compared to apparently
healthy persons) and therapeutic interventions in
the near future.13
AABs may have clinical relevance other than ser-
ving as a speciﬁc biomarker for diagnosing AID, as
has been shown by Edward K. L. Chan (USA), for
AABs directed against cytoplasmic rod and ring
structures (anti-RR antibodies), and by Nicola
Bizzaro (Italy) and Carlos A. Casiano (USA) for
anti-DFS70 antibodies and tumor-associated
AABs. Approximately 30% of hepatitis C viral
(HCV) infected patients treated with IFNa and
ribavirin develop AABs showing prominent cyto-
plasmic rod and ring (RR) structures, a pattern
referred to as AC-23 by the International
Consensus on ANA patterns (ICAP; website:
www.ANApatterns.org). The main target of anti-
RR AABs in HCV patients is IMPDH2, the key
rate-limiting enzyme involved in the guanosine tri-
phosphate (GTP) biosynthesis pathway. Ribavirin
is a well-established IMPDH2 inhibitor and is able
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to induce the formation of RR structures in vitro
and in vivo. These and other observations support
the hypothesis that anti-RR/IMPDH2 AAB pro-
duction is a drug-induced response due to the expos-
ure to ribavirin together with other contributing
factors.14 The impact of anti-RR antibodies on clin-
ical management of HCV and on the therapeutic
response is in discussion.15 Carlos A. Casiano
reviewed the diagnostic utility of tumor-associated
autoantigen (TAA) panels for AAB proﬁling in
cancer. He concluded that single tumor-associated
AABs (TAABs) have limited diagnostic/prognostic
value in cancer populations, whereas well-deﬁned
TAAB panels seem to be more promising. Such
TAAB panels should be carefully designed to dis-
tinguish, with high sensitivity and speciﬁcity,
patients with a particular cancer type from non-
cancer patients and from patients with other
cancer types. Results from multiplex TAAB proﬁl-
ing using diﬀerent platforms (e.g., ELISA, magnetic
beads, protein arrays) should be compared to
account for the possibility that technique-
associated exposure, inaccessibility, or destruction
of TAA epitopes inﬂuences the AAB response to a
TAA panel in a particular cancer type.16,17 Also,
diﬀerences in the stringency of cut-oﬀ values used
for exclusion or inclusion of a positive antibody
reaction can signiﬁcantly inﬂuence the frequency
of detected TAABs as well as the sensitivity and
speciﬁcity of a given TAAB panel.
AAB testing and diagnostic strategies
Harmonization and standardization of AAB testing
Luis E. C. Andrade (Brazil) reviewed the impact of
the heterogeneous nature of the ‘‘analyte AAB’’
and the use of diﬀerent technology platforms on
AAB test results as a major challenge for harmon-
ization of AAB testing.18 A sample from any given
patient may present diﬀerent reactivity when
assayed for antibodies to the same antigen in dif-
ferent immunoassays and no laboratory method
will have optimal performance for samples from
all patients. The potential confusion and hetero-
geneity in AAB testing can be attenuated by
promoting worldwide harmonization in standards
for disease speciﬁc AABs. Ongoing inter-
national quality assessment and standardization
initiatives have achieved some concrete results.19–21
A novel initiative, an International Autoantibody
Standardization (IAS) workshop started during the
12th IWAA in Sao Paulo in 2014, followed by the
2nd IAS workshop in Dresden 2015. Pier Luigi
Meroni (Italy) reviewed the current state and per-
spectives of the IAS initiative. The IAS workshops
aimed to stimulate harmonization and coordin-
ation of the independent eﬀorts of several related
initiatives (Australasian EQA, ASC/IUIS, EASI,
EULAR, and IFCC) and to promote an approxi-
mation between academic and industry scientists.
The common goal is to promote standardization
and improvement in laboratory diagnosis of AID.
Biotechnology companies are strongly encouraged
to join in this enterprise. The development of stand-
ards and better characterized reference materials is
the ﬁrst step towards a better understanding of the
challenges in AAB testing and trying to address
them. Joanna Sheldon (UK) focused on strategies
for building reference standards for AABs.22 Such
reference materials should be homogeneous, stable,
traceable, commutable, safe, ethical, available, and,
ideally, certiﬁed. She brieﬂy described the produc-
tion, evaluation and certiﬁcation process of a new
international reference preparation for antibodies
(IgG) to myeloperoxidase (ERM-DA476/IFCC).
The complexity and variability of the antigens,
the antibodies and the methods makes it unlikely
that the introduction of standards will completely
solve all the issues, however. It is more likely that it
will represent the start of the process of deﬁning the
antigen, the antibody and the method. Ultimately,
the goal is to reduce the variability in the available
tests aiming to improve patient diagnosis and over-
all care. A promising ongoing initiative is the con-
struction of pools with monospeciﬁc samples from
diﬀerent individuals.22 Another approach is to
establish monoclonal antibodies resembling the
reactivity of genuine and clinically relevant AABs.
During the last 50 years, the methods and anti-
gens used for ANA-associated rheumatic disease
(AARD) related AAB immunoassays have
been continuously and dramatically changing.23
Minoru Sato (Japan) discussed the current status
and issues of concern for AARD related AAB
immunoassays. He concluded that in recent years
a signiﬁcant problem is the release of new immuno-
assays without enough validation compared to
conventional or standard methods. Data by com-
mercial immunoassays including conventional
ELISA, multiplex immunoassays such as bead-
based immunoassays and line immunoassays
(LIA) for AABs diﬀer signiﬁcantly depending on
the manufacturer and do not always show the
intended speciﬁcity and sensitivity. Clinicians need
to be aware of this problem and use appropriate
AAB tests as an aid in the diagnosis.24,25 These
assays need to be carefully validated against a
standard assay such as immunoprecipitation and
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Ouchterlony double immunodiﬀusion or in clinical
studies to avoid inappropriate conclusions among
clinicians and researchers.26 Systematic evaluation
and standardization of assays are warranted ideally
before releasing the assay to the market or its use in
clinical research. Compared to this situation, the
standardization of diabetes speciﬁc AABs has
already reached a higher level. Michael Schlosser
(Germany) summarized the results of the Islet
Autoantibody Standardization Program (IASP)
2015 workshop. The IASP, a continuation of the
Diabetes Antibody Standardization Program
(DASP) of the Immunology of Diabetes Society,
was set up to evaluate and improve assays for
AABs associated with type 1 diabetes (T1D). The
IASP 2015 workshop aimed to assess the sensitiv-
ity/speciﬁcity and concordance of assays measuring
AABs to GAD (GADA), IA-2 (IA-2A), insulin
(IAA), and zinc transporter 8 (ZnT8A) in labora-
tories throughout the world. The results showed a
good concordance of most GADA, IA-2A, and
ZnT8A assays with a distinct pattern of reactivity
dependent on the assay format as well as on the
assay sensitivity. Especially for the IAA but also
for the other T1D-associated AABs, the assay per-
formance could still be improved in the majority of
laboratories to detect multiple AABs in the major-
ity of patient samples as a main criterion of T1D.27
Harmonization of the HEp-2 cell assay
and ANA testing
Diﬀerent committees and organizations aim to
achieve a better and more standardized approach
to AAB testing and reporting including the
International Union of Immunological Societies
(IUIS) Autoantibody Standardization Committee
(www.AutoAb.org), the European Autoimmunity
Standardisation Initiative (EASI; http://www.easi-
network.com/),20,28 European Consensus Finding
Study Group on AABs (ECFSG-EULAR),
and the Working Group on Harmonization of
Autoantibody Tests (WG-HAT) in the framework
of the International Federation of Clinical
Chemistry and Laboratory Medicine (http://www.
ifcc.org/ifcc-scientiﬁc-division/sd-working-groups/
harmonisation-of-autoantibody-tests-wg-hat/). At
the 12th IWAA (Sao Paulo, 2014) two separate
workshops (IAS and ICAP) were dedicated
to standardization and harmonization of AAB
testing and nomenclature.1 These initiatives were
continued as the 2nd IAS and 2nd ICAP work-
shops as an interlude of the Dresden Symposium
and the results were published recently.2,3 Luis
Andrade (Brazil) presented some key points of the
2nd ICAP, focusing on the ICAP website (www.
ANApatterns.org) as an important tool for
promoting ICAP concept and nomenclature.
Further discussed details were the translation of
the webpage to several idioms, the extension of
the classiﬁcation tree category by ‘‘composite pat-
tern’’, the potential inclusion of novel patterns and
the problem on how to classify an HEp-2 (ANA)
cell test with positive cytoplasmic (or mitotic) stain-
ing pattern.2
Michael Mahler (USA) reviewed the history,
current concepts and future directions for the
assessment of AABs to cellular antigens referred
to as antinuclear antibodies (ANA).23,29 While
there is increasing adoption of ANA testing, it
needs to be remembered that ANA test results are
only one component that leads to the diagnosis of
AARD. In addition, performance data (including
likelihood ratios, LR) of the method used to detect
ANA and appropriate explanation should be made
available to the clinician. Both indirect immuno-
ﬂuorescence (IIF) on HEp-2 cells and solid phase
assays (SPA) have their individual advantages and
limitations. Despite signiﬁcant evolution and
improvement in ANA and related AAB testing,
including the arrival of novel and promising tech-
nologies, several limitations still persist and need to
be addressed. First, the terminology and nomencla-
ture used to identify and refer to various AABs
needs to be standardized. Second, the classiﬁcation
criteria and nomenclature of individual AARD and
related AIDs must continue to evolve and keep
abreast of biomarker identiﬁcation. Third, the cor-
responding immunoassays and diagnostic plat-
forms used for the various clinical applications
need to be based on standardized reference samples
of deﬁned speciﬁcities. This possibility could
include the development and validation of disease
speciﬁc screening assays, i.e., SLE Screen, systemic
sclerosis (SSc) Screen, on SPA technologies.
Fourth, a clearly deﬁned strategy needs to be
developed to facilitate clinicians and laboratory sci-
entists alike becoming more familiar with and be
able to intelligently use objective interpretation of
AAB results through an understanding of receiver
operating characteristic (ROC) curve and LR ana-
lysis. Lastly, diagnostic algorithms need to be
adjusted to the clinical and laboratory setting that
take into consideration the medical specialty refer-
ral pattern, the sample testing volume and health
economic aspects (i.e., reimbursement). Martin
Blu¨thner (Germany) presented the experience
from ANA proﬁciency testing in the German
INSTAND e.V. quality assessment (QA) program
regarding ANA detection by the HEp-2 cell assays
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versus other ANA screening methods. The success
rate among the participants using non-IIF methods
for ANA detection was lower compared to that of
participants using the HEp-2 cell assay and was
clearly connected to the speciﬁc target antigens
recognized by the AABs in the sample material.
The increasing use of non-IIF screens and the
requirement of the revised guidelines of the
German medical association (RiliBA¨K) to partici-
pate in proﬁciency tests may indicate a possible
need for a separate QA platform that allows for
the inclusion of the non-IIF tests. Carlos Alberto
von Mu¨hlen (Brazil) reported the ﬁve-year experi-
ence of a Quality Control Program with
ANA-HEp-2 in Brazil. Advantages perceived by
participants were: comparison of own results with
those of other labs, anonymity, and getting
better ANA results through continuous education.
Laboratories not reaching expected results were
encouraged to retrain their technicians, evaluate
their microscopes and lamps, and reassess the qual-
ity of their commercial or in-house HEp-2 slides.
The current state of automated HEp-2 IIF
platforms to overcome labor-intensive and time-
consuming clinical work-up procedures was
reviewed by Manfred Herold (Austria).
Digitization of images and computer-assisted read-
ing of immunoﬂuorescence is one way to minimize
variation of pattern interpretation and quantiﬁca-
tion of ﬂuorescence intensity as the basis for ANA
titer estimation. Currently, seven automated IIF
reading systems are available.30 The positive and
negative agreement with conventional IIF inter-
pretation is similar for all automated systems and
ranges between 92% and 99% depending on studies
and sample selection.31 In samples with ANA test
results that are clearly negative or high-positive, the
automated decision for positive or negative reveals
a hit rate close to 100%. However, pattern recog-
nition is limited to a few main patterns. It can be
supposed that software improvement is ongoing
in all systems as the systems must be adapted in
keeping with updated recommendations in order
to recognize all recommended patterns.1
Multiplex AAB testing
Multiplex AAB testing is an important consider-
ation for cost-eﬀective serological autoimmune
diagnostics as well as a tool to search for novel
AABs. Dimitrios Bogdanos (Greece) reported the
usefulness of multiparametric AAB testing in the
diagnosis and diﬀerentiation of autoimmune liver
diseases. Later, Jan Damoiseaux (The Netherlands)
presented recent advances and potential caveats
of multiparametric autoimmune diagnostics.
Multiplex immunoassays have been widely intro-
duced in the diagnostic work-up of AID, in particu-
lar, of idiopathic inﬂammatory myopathies (IIM),
SSc, and autoimmune neurologic and liver disease
since these diseases are associated with a wide array
of AABs. Multiplex assays that have become a
diagnostic platform in routine laboratories include
line/dot immunoassays (LIA/DIA), addressable
laser bead immunoassays (ALBIA), and cell/tissue
arrays (may contain transfected cell lines). One
major problem of introducing multiplex immuno-
assays in the laboratory is the diﬃculty of validat-
ing the test for rare AABs and the lack of
quality management programs for these AAB.
Furthermore, the quantiﬁcation of AAB levels for
diagnosis and/or follow-up is not easily possible
with all multiplex immunoassays. Finally, the
antigen-composition of the assay is a critical
entity and the laboratory specialist has to decide
on how to interpret and report the distinct test
results. Xavier Bossuyt (Belgium) discussed the
design and implementation of protein microarrays
on planar surface for AAB multiplex testing used to
identify novel autoantigens and to proﬁle AABs
in various diseases. Protein microarrays are an
eﬃcient way to simultaneously test for speciﬁc
antibodies with small sample volumes. Although
the construction and application of an autoantigen
microarray to perform simple, low-sample volume,
ﬂuorescence-based, multiplex characterization of
human AAB responses have already been described
in 2002, such microarray systems have not been
introduced in clinical routine. He presented the
results of a technical evaluation of AMiDot, a
planar microarray system for detection of a panel
of AABs relevant for systemic rheumatic diseases.
A major problem is the inclusion of double-
stranded DNA (dsDNA) on protein microarrays.
Additional studies are warranted to further prove
the reliability of this technique for general applica-
tion in routine practice.
An important ﬁeld of multiplex testing is the sim-
ultaneous analysis of subtypes of anti-citrullinated
protein antibodies (ACPA) to yield additional
information about early diagnosis, prognosis and
response to therapy of rheumatoid arthritis (RA).
Johan Ro¨nnelid (Sweden) described the develop-
ment and initial use of a multiplex chip-based
assay (based on the Phadia/Thermoﬁsher ISAC
platform) for the detection of AABs against citrul-
linated peptides from various citrullinated proteins.
This approach deﬁnes an extended group of ACPA
positive RA patients as compared to the standard
anti-CCP2 assay. The extended group of ACPA
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positive patients shows the same gene–environment
association to shared epitopes and smoking, as ori-
ginally described for anti-CCP2 antibodies.
Another way of ACPA proﬁling is the immobiliza-
tion of citrullinated peptides (and control peptides)
on microarray sensor chips and analysis of AAB
binding by surface plasmon resonance imaging
(iSPR) of biomolecular interactions on the sensor
chip (Ger Pruijn, The Netherlands).
Petra Budde (Germany) described the develop-
ment of a Luminex bead-based assay, which
enables the analysis of 87 AABs in systemic lupus
erythematosus (SLE). Based on the individual
marker pattern, patients either belong to clusters
deﬁned by characteristic markers, or are phenotyp-
ically more overlapping with other AIDs. The ana-
lysis of the AAB reactivity yields at least four
diﬀerent reactivity groups. Therefore, multiplexed
analysis of AABs in SLE enables deﬁning an AAB
reactivity score and diﬀerent SLE patient clusters.32
This might support the stratiﬁcation of SLE
patients into more homogenous subgroups in clin-
ical studies thereby increasing the probability of
successful drug development. The potential of
mining for common reactivity patterns of AABs
against endogenous protein targets using clustered
AAB reactivity patterns was further shown by
Hans-Dieter Zucht (Germany).
A novel LIA employing a hydrophobic solid
phase for multiplex analysis of AAB against
phospholipid (aPL) and PL-associated proteins
was presented by Dirk Roggenbuck (Germany).
The performance characteristics of this new multi-
plexing assay technique demonstrated its usefulness
for aPL proﬁling. It was shown that this LIA can
determine aPL proﬁles with a better association
with the clinical phenotype in comparison to con-
sensus ELISAs. Thus, aPL analysis by LIA may be
a promising tool for the detection of APS-related
aPL, which can be explored for the investigation of
the relevance of aPL proﬁling as a risk factor in
APS.33 Results of a novel platform that combines
ANA screening and conﬁrmatory testing were dis-
cussed by Juliane Scholz (Germany).34 Microscopic
glass slides were employed as the solid phase matrix
with ﬁxed HEp-2 cells in the central part of the
wells for ANA screening, whereas autoantigen-
coated microparticles are immobilized in four per-
ipheral compartments for conﬁrmative testing by
IIF. The good concordance of the comparative
clinical analysis supports the assumption that the
novel CytoBead assay can provide at least the same
assay performance as classical two-tier ANA
testing.
In summary, diﬀerent multiplex platforms have
been developed in recent years as tools to identify
novel clinically relevant AABs, to search for diﬀer-
ent disease clusters within deﬁned AID entities, to
evaluate the clinical relevance of AAB proﬁles, to
improve serological AID diagnostics by including
novel and rare AAB speciﬁcities into multiplex
assay, and last but not least to optimize the work-
ﬂow in the routine laboratory. However, the main
challenge for routine use is standardization or har-
monization. Another potential problem refers to
operational reimbursement in places where multi-
plex testing is not a standardized procedure.
Novel AABs and novel aspects of AAB testing
Search for novel AABs
Diﬀerent proteomic approaches have been used to
ﬁnd novel AABs for possible application in daily
practice. Winfried Sto¨cker (Germany) described
the combination of the novel technique of
histo-immunoprecipitation and mass spectrometric
analysis of puriﬁed proteins as a potent strategy for
identiﬁcation of hitherto unknown antigens tar-
geted by AABs that are associated with various
neurological AIDs.35 By this strategy, the panel of
diagnostic markers for various neuroimmunologi-
cal conditions, predominantly autoimmune enceph-
alitis, can be expanded signiﬁcantly, supporting
rapid diagnosis and initiation of often life-
saving therapies (examples in Table 1). Peter
Schulz-Knappe (Germany) presented SeroTag, a
new screening pipeline for discovery of novel
AABs in AIDs. SeroTag comprises the generation
of a large antigen collection (7000 human recom-
binant proteins) and bead-based suspension arrays
(Luminex FlexMap 3D) to allow high throughput
serum sample processing with high accuracy,
followed by standard and advanced data mining
procedures. Using this strategy, candidates for
novel serological biomarkers have been found in
SLE and SSc patients (examples in Table 1).
cDNA phage display and serologic antigen selec-
tion were used by Laura de Bock and Liesbeth de
Winter (Belgium) to screen for novel AABs in RA
and multiple sclerosis (see Table 1) and Laura
Palmer (Belgium) to screen for candidate antibody
biomarkers in spinal cord injury. Protein micro-
arrays were also described by Xavier Bossuyt
(Belgium) as useful tools to look for novel AABs.
The search for novel AABs is important in
several reasons. First, there are still many
diagnostic gaps in serological diagnosis of AID
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(i.e., seronegative RA, IIM, SSc, autoimmune
neurologic diseases) that have to be ﬁlled. Second,
AAB tests with high diagnostic speciﬁcity and high
predictive values are required for the early deﬁnite
diagnosis of AID and indication for early initiation
of the adequate therapy. This is especially import-
ant in the early diagnosis of other immune
mediated disease that lack serological markers
such as multiple sclerosis. Third, the identiﬁcation
of novel clinically relevant AAB broadened the
spectrum of autoimmune diagnostics and permits
the diagnosis of former idiopathic diseases like
idiopathic encephalopathies and paraneoplastic
diseases. Candidate AABs for improving AID diag-
nosis presented at the meeting are shown in Table 1.
The broadened spectrum of clinically relevant
AABs may also lead to the diﬀerentiation of clinical
entities or subtypes with diﬀerent prognosis and
therapy as summarized by Tsuneyo Mimori and
Yuji Hosono (Japan) for IIM and interstitial lung
disease (ILD).36 Anti-aminoacyl-tRNA synthetase
(ARS) and anti-melanoma diﬀerentiation-
associated gene 5 (MDA5) antibodies are closely
associated with ILD in IIM patients. It is important
to note that anti-ARS antibodies (especially the
non-Jo-1 anti-ARS antibodies, i.e., PL7, PL12,
EJ, OJ, KS antibodies) as well as anti-MDA5 anti-
bodies may be detectable in ILD patients without
myositis and may serve as biomarkers for these
subsets of disease that often requires intensive
immunosuppressive therapy. As another example,
the state and perspectives in diﬀerential diagnosis
for AAB-mediated neuronal autoimmunity (white
matter diseases, psychiatric disorders, catatonia,
post-infectious diseases, refractory seizures, status
epilepticus, movement disorders, encephalitis of
unclear etiology) was reviewed by Romana
Ho¨ftberger (Austria).37
Because more and more novel and rare AABs
are applicable in routine diagnostics by LIAs,
ELISAs and cell-based immunoassays using auto-
antigen transfected cell lines, every laboratory has
the potential of expanding the spectrum of AAB
testing. However, some limitations have to kept in
mind, such as inadequate or ongoing evaluations
studies in case of rare diseases or ethnical diﬀer-
ences of the clinical relevance and problems in
test harmonization because of the lack of reference
material and even positive controls in case of
rare AABs.
Search for further clinical aspects of AAB testing
Falk Hiepe (Berlin, Germany) discussed the role of
AABs and other biomarkers for personalized treat-
ment in SLE. AABs directed against dsDNA are
considered as diagnostic marker for SLE, are asso-
ciated with nephritis, correlate with disease activity
and might precede ﬂares. However, there are an
unmanageable number of anti-dsDNA assays on
the market, which complicate the interpretation of
results. Nowadays, the laboratories often prefer
ELISAs, which have lower diagnostic speciﬁcity
in comparison to the traditional FARR assay and
Crithidia IIF test. It should be emphasized that
the diﬀerent available ELISA kits may clearly
vary regarding sensitivity, speciﬁcity, correlation
with disease activity and association with
renal involvement. Consequently, better standard-
ization of commercially available assays is needed.
Table 1 Candidates for novel clinically relevant autoantibodies
Autoantigen AAB–clinical association
ATP1A3: ATPase for Naþ and Kþ Paraneoplastic brainstem/ cerebellar syndrome with
ataxia, tetraparesis, dysarthria, dysphagia
W. Sto¨cker (Germany)
BICD2: C-terminal 218 AA (coiled coil region) of the
Bicaudal D homolog 2 (Drosophila) protein
In 30% of SSc (specificity 95%), lower risk of
pulmonary fibrosis
J. Schulte-Pelkum (Germany)
Cohesin: subunits of the cohesin complex (SA-1, SA-2,
and SMC3)
Three patients with idiopathic inflammatory myopathy M. Tanaka (Japan)
Flotilin-1/2: ubiquitous membrane protein Optic neuritis W. Sto¨cker (Germany)
IgLON5: neuronal cell adhesion protein of the Ig
superfamily
‘‘REM sleep behavior disorder,’’ brainstem-limbic
dysfunction
R. Ho¨ftberger (Austria)
ITPR1: inositol-1,4,5-trisphosphate receptor 1 Cerebellar ataxia W. Sto¨cker (Germany)
NCDN: human neurochondrin isoform 1 (79 kDa) Paraneoplastic cerebellitis with brainstem syndrome W. Sto¨cker (Germany)
PPP1R2: aminoterminal half of the protein phosphatase
1 regulator 2
In 20% of SSc (specificity 95%) J. Schulte-Pelkum (Germany)
SPAG16: sperm-associated antigen 16 In 22% of multiple sclerosis (MS) patients (specificity
93%), highest antibody levels and 34% positive in
primary progressive MS patients
L. de Bock (Belgium)
UH-RA.1 and -RA.21: peptides selected by screening of
RA cDNA phage display library
In 19–33% of early RA (specificity 82–96%), present
also in sero-negative RA
L. de Winter (Belgium)
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AABs can be secreted by either short-lived
plasmablasts or long-lived memory plasma cells.
Persistently high AABs serum levels such as
anti-dsDNA antibodies despite treatment with
immunosuppressive drugs or biologics targeting B
cells indicate that AABs are secreted by long-lived
memory plasma cells. As long-lived memory
plasma cells reside in bone marrow and inﬂamed
tissues they elude the diagnostics in patients.
Therefore, there is still a need for biomarkers that
predict clinical ﬂares in SLE. The role of AABs in
RA as predictors of disease outcome and response
to therapy was reviewed by Gu¨nter Steiner
(Austria). It is well known that rheumatoid factors
(RF) and ACPA are predictors of disease develop-
ment in early arthritis subjects. Furthermore, they
are independent predictors of radiographic progres-
sion. Among the anti-CCP positive patients, the
rate of joint destruction between patient with high
and low anti-CCP levels did not diﬀer, however.
There is no (anti-CCP) or only weak (RF) correl-
ation with disease activity. In contrast to RF and
ACPA, AABs to the heterogeneous nuclear ribonu-
cleoprotein A2 (anti-RA33 antibodies) are not
associated with radiographic progression but
rather seem to predict a more favorable outcome.
No single AAB seems to be suﬃciently reliable to
predict therapeutic response in individual patients.
IgA-RF may be helpful in predicting a poor
response to TNF inhibition. On the other hand,
IgG-RF and certain ACPA subtypes may be help-
ful in predicting a good response to B cell depletion
in seropositive patients. Ger Pruijn (The
Netherlands) showed that AAB against citrulli-
nated a-enolase peptide-1 (CEP-1) represent a
prevalent subclass of ACPA and may have add-
itional predictive value for the development of
RA. More multi-center studies urgently needed to
evaluate the predictive, prognostic, and theranostic
relevance of RA associated AABs that may include
a broader spectrum of ACPA speciﬁcities (e.g.,
AABs against CEP-1 and citrullinated collagen
II), AABs against peptides with other modiﬁcation
than citrullination (carbamylation, acetylation),
anti-peptidylarginine deiminase (PAD) antibodies
as well as novel identiﬁed AAB.38,39
The DFS70 AAB–autoantigen system
Carlos A. Casiano (USA) reviewed the enigmatic
DFS70 AAB–autoantigen system.40 DFS70, most
commonly known outside the ﬁeld of autoimmunity
as the 75 kDa lens epithelium derived growth factor
protein (LEDGFp75), was named because of the
typical ‘‘dense ﬁne speckled’’ (DFS) nuclear pattern
on HEp-2 cells and reactivity with a 70 kDa protein
in western immunoblots by the corresponding AAB.
This protein is a ubiquitous, multi-functional stress
response protein that plays key roles in the patho-
physiology of major human diseases, particularly
cancer, HIV/AIDS, and certain eye diseases. AABs
targeting this protein are present in varied frequen-
cies in a plethora of inﬂammatory diseases and clin-
ical conditions not associated with AARD, as well
as in apparently healthy individuals. Several studies
have shown that anti-DFS70 antibodies are very
rarely found in AARD patients.41,42 If they are
found in the absence of disease-speciﬁc AABs, they
tend to exclude an AARD diagnosis, suggesting that
they could be useful exclusion biomarkers of
AARD. Although further studies are needed, the
determination of anti-DFS70 antibodies is included
into routine diagnostics for better diﬀerentiating
ANA positive patients with rheumatic symptoms
not caused by AARD from patients with deﬁnite
AARD. It is therefore of utmost importance in the
routine practice, that the DFS pattern, deﬁned as
‘‘AC-2 pattern’’ by ICAP, should be diﬀerentiated
from homogenous as well as the diﬀerent speckled
nuclear patterns.1 However, the recognition of the
DFS pattern byHEp-2 IIF is not suﬃcient for accur-
ate deﬁnition of anti-DFS70 antibodies as was
shown by Nicola Bizzaro (Italy). Conﬁrmatory
tests are required such as CIA, DIA/LIA, ELISA,
or HEp-2 cell IIF with serum pre-adsorption
using DFS70 recombinant protein containing
autoepitope.43
Perspective
Novel results regarding AAB research and
improvements of diagnostics of AIDs, including
harmonization and standardization of AAB ana-
lyses, will be presented and discussed at the 13th
Dresden Symposium on Autoantibodies in
September 2017 (www.gﬁd-ev.de).
Declaration of Conflicting Interests
The author(s) declared no potential conﬂicts of
interest with respect to the research, authorship,
and/or publication of this article.
Funding
The author(s) received no ﬁnancial support for the
research, authorship, and/or publication of this
article.
From AAB research to standardized diagnostic assays
K Conrad et al.
794
Lupus
References
1 Chan EKL, Damoiseaux J, Carballo OG, et al. Report of the first
international consensus on standardized nomenclature of antinuc-
lear antibody HEp-2 cell patterns 2014–2015. Front Immunol 2015;
6:DOI: 10.3389/fimmu.2015.00412.
2 Damoiseaux J, von Mu¨hlen CA, Garcia-De La Torre I, et al.
International Consensus on ANA Patterns (ICAP): the bumpy
road towards a consensus on reporting ANA results. Autoimmun
Highlights 2016; DOI: 10.1007/s13317-016-0075-0.
3 Chan EKL, Damoiseaux J, de Melo Cruvinel W, et al. Report on
the second International Consensus on ANA Pattern (ICAP)
workshop in Dresden 2015. Lupus 2016; this issue.
4 Conrad K, Andrade LEC, Chan EKL, Pruijn GJM, Steiner G,
Shoenfeld Y (eds). From Autoantibody Research to Standardized
Diagnostic Assays in the Management of Human Diseases, Report
on the 12th Dresden Symposium on Autoantibodies. Lengerich,
Germany: Pabst Science Publishers, 2015.
5 Perricone C, Versini M, Ben-Ami D, et al. Smoke and autoimmun-
ity: the fire behind the disease. Autoimmun Rev 2016; 15: 354–374.
6 Versini M, Aljadeff G, Jeandel P-Y, Shoenfeld Y. Obesity: an add-
itional piece in the mosaic of autoimmunity. IMAJ 2014; 16:
619–621.
7 Lerner A, Matthias T. Changes in intestinal tight junction perme-
ability associated with industrial food additives explain the rising
incidence of autoimmune disease. Autoimmun Rev 2015; 14:
479–489.
8 Bogdanos DP, Smyk DS, Rigopoulou EI, Sakkas LI, Shoenfeld Y.
Infectomics and autoinfectomics: a tool to study infectious-induced
autoimmunity. Lupus 2015; 24: 364–373.
9 Meroni PL. Anti-beta2 GPI epitope specificity: from experimental
models to diagnostic tool. Lupus 2016; this issue.
10 Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syn-
drome: antibodies to Domain 1 of b2-glycoprotein 1 correctly clas-
sify patients at risk. J Thromb Haemostasis 2015; 13: 782–787.
11 Mahler M, Norman GL, Meroni PL, Khamashta M.
Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising
candidate biomarker for risk management in antiphospholipid syn-
drome. Autoimmun Rev 2012; 12: 313–317.
12 Fickentscher C, Magorivska I, Janko C, et al. The pathogenicity of
anti-beta2GP1-IgG autoantibodies depends on Fc glycosylation.
J Immunol Res 2015; DOI: org/10.1155/2015/638129.
13 Herrmann M. Importance of glycan accessibility at the Fc part of
IgG for patients with rheumatic diseases. Lupus 2016; this issue.
14 Calise SJ, Keppeke GD, Andrade LE, Chan EKL. Anti-rods/rings:
a human model of drug-induced autoantibody generation. Front
Immunol 2015; 6:DOI: 10.3389/fimmu.2015.00041.
15 Carcamo W, Ceribelli A, Calise SJ, et al. Differential reactivity to
IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness
to pegylated interferon-alpha/ribavirin therapy in US and Italian
HCV patients. J Clin Immunol 2013; 33: 420–426.
16 Yang Z, Chevolot Y, Ge´hin T, et al. Improvement of protein
immobilization for the elaboration of tumor-associated antigen
microarrays: application to the sensitive and specific detection of
tumor markers from breast cancer sera. Biosens Bioelectron 2013;
40: 385–392.
17 Murphy MA, O’Connell DJ, O’Kane SL, et al. Epitope presenta-
tion is an important determinant of the utility of antigens identified
from protein arrays in the development of autoantibody diagnostic
assays. J Proteomics 2012; 75: 4668–4675.
18 Pereira KM, Dellavance A, Andrade LE. The challenge of identi-
fication of autoantibodies specific to systemic autoimmune rheum-
atic diseases in high throughput operation: proposal of reliable and
feasible strategies. Clin Chim Acta 2014; 437: 203–210.
19 Chan EK, Fritzler MJ, Wiik A, et al. The IUIS/WHO/AF/CDC
committee for the standardization of autoantibodies in
rheumatic and related diseases – Autoantibody Standardization
Committee in 2006. Autoimmun Rev 2007; 6: 577–580.
20 Shoenfeld Y, Cervera R, Haass M, et al. EASI – The European
Autoimmunity Standardisation Initiative: a new initiative that can
contribute to agreed diagnostic models of diagnosing autoimmune
disorders throughout Europe. Ann N Y Acad Sci 2007; 1109:
138–144.
21 Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I,
Borghi MO. Standardization of autoantibody testing: a paradigm
for serology in rheumatic diseases. Nat Rev Rheumatol 2014; 10:
35–43.
22 Sheldon J, Dellavance A. Strategies for building reference stand-
ards for autoantibodies. Front Immunol 2015; 6:DOI: 10.3389/
fimmu.2015.00194.
23 Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts
and future directions for the assessment of autoantibodies to cel-
lular antigens referred to as anti-nuclear antibodies. J Immunol Res
2014; DOI: 10.1155/2014/315179.
24 Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of
enzyme immunoassay kits for detection of antinuclear autoantibo-
dies of defined specificities. II. Potential for quantitation of anti-
body content. J Rheumatol 2002; 29: 68–74.
25 Fritzler MJ, Wiik A, Tan EM, et al. A critical evaluation of enzyme
immunoassay kits for detection of antinuclear autoantibodies of
defined specificities. III. Comparative performance characteristics
of academic and manufacturers’ laboratories. J Rheumatol 2003;
30: 2374–2381.
26 Satoh M, Tanaka S, Chan EK. The uses and misuses of multiplex
autoantibody assays in systemic autoimmune rheumatic diseases.
Front Immunol 2015; 6:DOI: 10.3389/fimmu.2015.00181.
27 Williams AJK, Lampasona V, Schlosser M, et al. Detection of
antibodies directed to the N-terminal region of GAD is dependent
on assay format and contributes to differences in the specificity of
GAD autoantibody assays for type 1 diabetes. Diabetes 2015; 64:
3239–3246.
28 Damoiseaux J, Agmon-Levin N, Van Blerk M, et al. From ANA
screening to antigen specificity: an EASI survey on the daily prac-
tice in European countries. Clin Exp Rheumatol 2014; 32: 539–546.
29 Agmon-Levin N, Damoiseaux J, Shoenfeld Y. Comment on:
‘Detection of antinuclear antibodies: added-value of solid phase
assay?’ by Bossuyt and Fieuws. Ann Rheum Dis 2014; 73: e11.
30 Tozzoli R, Antico A, Porcelli B, Bassetti D. Automation in indirect
immunofluorescence testing: a new step in the evolution of the
autoimmunology laboratory. Autoimmun Highlights 2012; 3:
59–65.
31 Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A.
Automated tests of ANA immunofluorescence as throughput auto-
antibody detection technology: strengths and limitations. BMC
Med 2014; 12: 38.
32 Budde P, Zucht HD, Vordenba¨umen S, et al. Multiparameteric
detection of autoantibodies in SLE. Lupus 2016; this issue.
33 Roggenbuck D, Somma V, Schierack P, Borghi MO, Meroni PL.
Autoantibody profiling in APS. Lupus 2014; 23: 1262–1264.
34 Scholz J, Grossmann K, Knu¨tter I, et al. Second generation ana-
lysis of antinuclear antibody (ANA) by combination of screening
and confirmatory testing. Clin Chem Lab Med 2015; 53:
1991–2002.
35 Scharf M, Miske R, Heidenreich F, et al. Neuronal Naþ/Kþ
ATPase is an autoantibody target in paraneoplastic neurologic
syndrome. Neurology 2015; 84: 1673–1679.
36 Nakashima R, Hosono Y, Mimori T. Clinical significance and new
detection system of autoantibodies in myositis with interstitial lung
disease. Lupus 2016; this issue.
37 Ho¨ftberger R. Neuroimmunology: an expanding frontier in auto-
immunity. Front Immunol 2015; 6:DOI: 10.3389/fimmu.2015.00206.
38 Cantagrel A, Degboe´ Y. New autoantibodies associated with
rheumatoid arthritis recognize post-translationally modified self-
proteins. Joint Bone Spine 2016; 83: 11–17.
39 Shi J, van Veelen PA, Mahler M, et al. Carbamylation and anti-
bodies against carbamylated proteins in autoimmunity and other
pathologies. Autoimmun Rev 2014; 13: 225–230.
40 Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: an enig-
matic autoantigen at the interface between autoimmunity, AIDS,
and cancer. Front Immunol 2015; 6:DOI: 10.3389/fimmu.2015.
00116.
From AAB research to standardized diagnostic assays
K Conrad et al.
795
Lupus
41 Conrad K, Ro¨ber N, Rudolph S, Mahler M. DFS70 antibodies –
biomarkers for the exclusion of ANA-associated autoimmune
rheumatic diseases. J Lab Med 2015; DOI: 10.1515/labmed-2015-
0040.
42 Mahler M, Hanly JG, Fritzler J. Importance of the dense fine
speckled pattern on HEp-2 cells and anti-DFS70 antibodies for
the diagnosis of systemic autoimmune diseases. Autoimmun Rev
2012; 11: 642–645.
43 Mahler M, Meroni PL, Andrade LE, et al. Towards better under-
standing of the clinical association of anti-DFS70 autoantibodies.
Autoimmun Rev 2016; 15: 198–201.
From AAB research to standardized diagnostic assays
K Conrad et al.
796
Lupus
